HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: In fact, the pan-HDAC inhibitors Vorinostat and Romidepsin have already been granted Food and Drug Administration approval for treatment of cutaneous T cell lymphoma [54, 55].